

Nonsynonymous Amino Acid Mutations in gp120 Binding Sites are Related to Progression of HIV-1

Matthew Allegretti and Anindita Varshneya
BIOL 368: Bioinformatics Laboratory
Loyola Marymount University
November 8, 2016

Outline


- 1. Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.**
- 2. Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.**
- 3. Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.**
- 4. Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.**
- 5. Other studies identified position 317 in gp120 essential for antibody recognition.**

Outline


1. **Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.**
2. Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.
3. Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.
4. Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.
5. Other studies identified position 317 in gp120 essential for antibody recognition.

Amino Acids are Categorized According to R Groups

Hydrophobic



© 2010 Pearson Education, Inc.



Hydrophilic

Nonsynonymous amino acid mutations are mutations across these two groups.

Amino Acids in Binding Sites Must be Highly Specific for Proteins to Successfully Bind With Ligands





Figure 4-27 Essential Cell Biology 3/e (© Garland Science 2010)

Interactions Between gp120 and CD4 cells Impact Progression of HIV-1



Outline

1. Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.
2. **Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.**
3. Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.
4. Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.
5. Other studies identified position 317 in gp120 essential for antibody recognition.

Mutations in Four Subjects' Protein Sequences Were Analyzed to Determine Functional Differences

Question: How do mutations in gp120 affect function of the protein?

Hypothesis: Nonsynonymous mutations in gp120 in key locations will most greatly affect protein function.

- Subjects 4(RP), 9(MP), 11(RP), and 14(MP)
 - Different progressor groups, but same dS/dN values
- Clones collected from Visit 1 and Visit 4
 - Compare extent of change in structure over time
- Amino acids 269 - 363 in gp120 analyzed

Subjects Have Identical dS/dN Values in Different Progressor Groups

Table 1. Summary data on 15 seroconverters

Subject	No. of observations	Baseline			Annual rate of CD4 T cell decline	Slope of change in intravisit nucleotide differences per clone per year	Slope of divergence (% nucleotides mutated from baseline consensus sequence per year)	Median dS/dN
		CD4	Median intravisit nucleotide differences among clones	Virus copy number (×10 ³)				
Rapid Progressor								
Subject 4	4	1,028	0.90	6.8	−593	4.64	2.09	0.0
Subject 10	5	833	1.71	99.3	−363	3.16	1.00	0.2
Subject 11	4	753	2.27	62.2	−363	1.11	0.32	0.0
Subject 15	4	707	15.16	171.0	−362	−2.94	0.68	0.7
Subject 3	5	819	1.82	302.5	−294	0.53	0.74	1.0
Subject 1	3	464	5.64	307.6	−117	5.10	1.55	0.3
Moderate Progressor								
Subject 7	5	1,072	2.27	317.6	−392	−0.79	1.35	1.3
Subject 8	7	538	1.24	209.0	−92	1.68	1.16	0.5
Subject 14	9	523	1.00	50.9	−51	1.69	0.60	0.0
Subject 5	5	749	2.50	260.6	−41	0.06	0.50	1.4
Subject 9	8	489	9.49	265.0	−11	1.58	1.21	0.0
Subject 6	7	405	2.82	321.4	52	1.92	0.82	0.4
Nonprogressor								
Subject 2	5	715	1.64	21.6	30	1.32	0.49	1.8
Subject 12	6	772	2.80	5.1	44	0.62	0.13	0.9
Subject 13	5	671	0.87	1.7	53	0.53	0.28	3.5

Major Mutations in Protein Sequences were Measured According to the Number and Importance of Substitutions

- We measured the number of positions with:
 - Any amino acid substitutions
 - Major substitutions (hydrophobic to hydrophilic or vice versa)
 - Multiple major substitutions across clones

Outline

1. Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.
2. Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.
3. **Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.**
4. Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.
5. Other studies identified position 317 in gp120 essential for antibody recognition.

Subject 4 (RP)


```

S4V4-11 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-RVGD IRQA
S4V4-9 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-RVGD IRQA
S4V4-12 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-RVGD IRQA
S4V4-10 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-RVGD IRQA
S4V4-3 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-RVGD IRQA
S4V4-13 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGLGSSSFYTTG-RIGD IRQA
S4V4-2 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPGRSFYTTG-IVGD IRQA
S4V4-8 EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-II GD IRQA
S4V4-5 [4] EVVIRSENFTHNARI IIVQLNESVEINCTRPDNNTVRRIP IGPSSSFYTTG-RIGD IRQA
S4V4-1 EVVIRSENFTHNARI IIVQLNRSVEINCTRPDNNTVRRIP IGPSSSFYTTG-RIGD IRQA
S4V4-7 EVVIRSENFTHNARI IIVQLNRSVEINCTRPNNNTIRRIP IGPGRAPYTTG-RIGN IRQA
S4V4-4 EVVIRSENFTHNARI IIVQLNRSVEINCTRPNNNTIRRIP IGPGRAPYTTG-RIGN IRQA
S4V1-3 [3] EVVIRSENFTHNARI IIVQLNRSVEINCTRPNNNTIRRIP IGPGRAPYTTG-RIGD IRPA
S4V1-1 EVVIRSENFTHNARI IIVQLNRSVEINCTRPNNNTIRRIP IGPGRAPYTTG-RIGD IRPA
S4V1-2 [11] EVVIRSENFTHNARI IIVQLNRSVEINCTRPNNNTIRRIP IGPGRAPYTTG-RIGD IRQA
Huang EVVIRSDNPTNNART IIVQLRESVEINCTRPQNTRKSI IGPGRAPYTTGE II GD IRQA
consensus EVVIRSENFTHNARI IIVQLNESVEINCTRPdnnTVrkIP IGPg■FYTTG-riGdIRqA


S4V4-11 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-9 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-12 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-10 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-3 HCNI SRTK■NNTLKL I ANKLR EQPGRNKT I IFNQSS
S4V4-13 HCNI SRTK■NNTLKL I ANKLR EQPGRNKT I IFNQSS
S4V4-2 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-8 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-5 [4] HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-1 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-7 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V4-4 HCNI LEAK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V1-3 [3] HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V1-1 HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
S4V1-2 [11] HCNI SRTK■NNTLKL I VNKLR EQPGRNKT I IFNQSS
Huang HCNI SAR■NDTLKQ I VIKLR EQPGRNKT I IFNQSS
consensus HCNI ■rtK■NntLKL I VnkLR EQPgNKT I IFNqSS

```

Subject 4 (RP)



Subject 4 (RP)



Subject 11 (RP) Indicates Several Locations With Major Amino Acid Mutations

```



S11V4-7      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-4      -----EVIIRSENFsNNAKNIIVQLNESV
S11V1-2      -----EVIIRSENFsNNAKNIIVQLNESV
S11V1-3[4]   -----EVIIRSENFsNNAKNIIVQLNESV
S11V1-6      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-5      -----EVIIRSENFsNNAKNIIVQLNESV
S11V1-7      -----EVIIRSKNEFsNNAKNIIVQLNESV
S11V1-1      -----EVIIRSKNEFsNNAKNIIVQLNESV
S11V1-4      -----EVIIRSKNEFsNNAKNIIVQLNESV
S11V1-5      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-3      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-1[2]   -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-8      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-2      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-9      -----EVIIRSENFsNNAKNIIVQLNESV
S11V4-6      -----EVIIRSENFsNNAKNIIVQLNESV
2B4C_G_Chain_G_ STVQCTHGIRPVVSTQLLLNGSLABEEVIRSDNEfTNAKTIIVQLKESV
consensus      -----EVIIRSENFsNNAKNIIVQLNESV

S11V4-7      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-4      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-2      VITCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-3[4]   VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-6      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-5      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-7      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-1      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-4      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V1-5      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-3      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-1[2]   VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-8      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-2      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-9      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
S11V4-6      VINCTRDPNTIKQRIIHIGPGRPFYTTG-IKGNIRQAHCNVsRGQWnKTL
2B4C_G_Chain_G_ VINCTRDP-NQNTRKSIHIGPGRAFYTTGSIIIGDIRQAHCNIIRAKWnDnTL
consensus      vInCTRdpntikqriIHIGPGRPFYTTG-IkGnIRQAHCNVsRgqWnKTL


S11V4-7      EQVVRKLREqYGLNKTIvFKQPI
S11V4-4      EQVVRKLREqYGLNKTIvFKQPI
S11V1-2      EQVVRKLREqYGLNKTIvFKQPI
S11V1-3[4]   EQVVRKLREqYGLNKTIvFKQPI
S11V1-6      EQVVRKLREqYGLNKTIvFKQPI
S11V4-5      EQVVRKLREqYGLNKTIvFKQPI
S11V1-7      EQVVRKLREqYGLNKTIvFKQPI
S11V1-1      EQVVRKLREqYGLNKTIvFKQPI
S11V1-4      EQVVRKLREqYGLNKTIvFKQPI
S11V1-5      EQVVRKLREqYGLNKTIvFKQPI
S11V4-3      EQVVRKLREqYGLNKTIvFKQPI
S11V4-1[2]   EQVVRKLREqYGLNKTIvFKQPI
S11V4-8      EQVVRKLREqYGLNKTIvFKQPI
S11V4-2      EQVVRKLREqYGLNKTIvFKQPI
S11V4-9      EQVVRKLREqYGLNKTIvFKQPI
S11V4-6      EQVVRKLREqYGLNKTIvFKQPI
2B4C_G_Chain_G_ KQIVIKLREqYGFNKTIVFKQPI
consensus      eQvVrKLREqYgLNKTIvFkqpi

```


Subject 11 (RP) Has Mutations on gp120 Near Antibody Interaction Sites



Subject 11 (RP) Has Mutations on gp120 Near Antibody Interaction Sites



Outline


1. Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.
2. Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.
3. Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.
4. **Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.**
5. Other studies identified position 317 in gp120 essential for antibody recognition.

Subject 9 (MP)


```
S9V1-4      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V1-1[2]   EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V1-2      EVVIRSANPTDNARTIIIVQLKEHVEINCARPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-11     EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-2      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-10     EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-7      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-8      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-9      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-5      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-6      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-3      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-4      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V4-1      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V1-3      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
S9V1-5      EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
Huang      EVVIRSDNPTDNARTIIIVQLRESVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
consensus  EVVIRSANPTDNARTIIIVQLKEHVEINCTRPNNNTRRSINIGPGRAPYATGTIIGDIRQA
```

```
S9V1-4      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V1-1[2]   HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V1-2      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-11     HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-2      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-10     HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-7      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-8      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-9      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-5      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-6      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-3      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-4      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V4-1      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V1-3      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
S9V1-5      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
Huang      HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
consensus  HCNISGARWMDTLRQIVERLREQFENRTIVFNHSS
```

Subject 9 (MP)



Subject 9 (MP)



Subject 14 (MP) Indicates Multiple Major Mutations Between Clones at an Interaction Site


```

S14V1-4      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSINTGPGRAPYATGDI
S14V1-3      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V1-6      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V1-5      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V1-1[?]   -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V1-2      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-7[2]   -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-8      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-9[2]   -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-1      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-6      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-4      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-3      -----EVVIRSENFPTNNAKIIVQPNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-2      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-1D     -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
S14V4-5      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
2B4C_G_Chain_G_ GSIABEEVVIRSDNFTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI
consensus      -----EVVIRSENFPTNNAKIIVQLNESVEINCTRPNNNTRRSIMIGPGRAPYATGDI

S14V1-4      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V1-3      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V1-6      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V1-5      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V1-1[?]   GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V1-2      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-7[2]   GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-8      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-9[2]   GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-1      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-6      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-4      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-3      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-2      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-1D     GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
S14V4-5      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----
2B4C_G_Chain_G_ GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSSGGDPEIVMHSFNCGEFF
consensus      GDIRQABCNLSRAKWNNTLRQIVYKLRQFGNNKTIIFNQSS-----

```


Subject 14 (MP) Indicates Multiple Major Mutations Between Clones at an Interaction Site



Outline

1. Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.
2. Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.
3. Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.
4. Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.
5. **Other studies identified position 317 in gp120 essential for antibody recognition.**

Subject 9 and 14 Carry Mutations at an Antibody Recognition Site

- Edlefsen et al. 2015

Future Work

- See if mutations at site 317 persist in other subjects in each progressor group
-

Summary

- 1. Nonsynonymous mutations in binding sites affects gp120 and CD4 binding.**
- 2. Variability of four subjects' clones were analyzed across two visits to determine structural and functional differences.**
- 3. Rapid progressors showed major mutations across all clones, but few highly variable amino acids appeared.**
- 4. Moderate progressors showed multiple major mutations at amino acids that interact with binding sites.**
- 5. Other studies identified position 317 in gp120 essential for antibody recognition.**

Acknowledgements



Thank you Dr. Kam D. Dahlquist, Department of Biology at Loyola Marymount University, and colleagues in BIOL 368.

References

- Edlefsen, P. T., Rolland, M., Hertz, T., Tovanabutra, S., Gartland, A. J., Magaret, C. A., et al. (2015). Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. *PLoS Comput Biol*, 11(2), e1003973.
- Huang, C. C., Tang, M., Zhang, M. Y., Majeed, S., Montabana, E., Stanfield, R. L., ... & Wyatt, R. (2005). Structure of a V3-containing HIV-1 gp120 core. *Science*, 310(5750), 1025-1028.
- Kirchherr, J. L., Hamilton, J., Lu, X., Gnanakaran, S., Muldoon, M., Daniels, M., Kasongo, W., et al. (2011). Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. *Virology*, 409(2), 163-174. DOI: 10.1016/j.virol.2010.09.031
- Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature*, 393(6686), 648-659. DOI: 10.1038/31405
- Markham, R.B., Wang, W.C., Weisstein, A.E., Wang, Z., Munoz, A., Templeton, A., Margolick, J., Vlahov, D., Quinn, T., Farzadegan, H., & Yu, X.F. (1998). Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. *Proc Natl Acad Sci U S A*. 95, 12568-12573. doi: 10.1073/pnas.95.21.12568